Page 4 - Indian Pharma

The next online tonic: E-majors, corporate giants eye e-pharmacy business

Amazon, Reliance recently announced their foray into e-pharma sector

Torrent Pharma Q2 net up 27% despite dip in US and Brazil revenues

Firm's consolidated total revenue for the quarter, however, fell marginally by 0.7% to stand at Rs 2,023 crore

Best time to invest in pharma, medical device sector: Sadananda Gowda

This is the most opportune time to invest in the Indian pharma and medical device sector as the government is extending production linked incentives for new manufacturing units, Gowda has said

New launches in key categories to trigger AstraZeneca Pharma's growth

Higher share of patented products, scope for margin improvement and chronic portfolio are key positives

RIL picks majority stake in Netmeds: How it became 'India ki pharmacy'

Promoted by Dadha Pharma, Netmeds is one of the earliest players in online pharmacy having incorporated in 2015

Chemist body warns against Amazon's entry into online pharmacy space

The letter has also been addressed to Prime Minister Narendra Modi, Union Home Minister Amit Shah and other top ministers and government officials

China crisis, India scouting for APIs a shot in arm for sick pharma PSU

Govt is trying to reduce dependence on China for APIs and develop indigenous sources

Covid-19 crisis: Indian drug companies yet to get nod to market remdesivir

The USFDA granted remdesivir an emergency use authorization for the treatment of hospitalized patients with severe Covid-19

Trump's focus on local drugs not immediate concern: Indian pharma industry

US is one of the major export destinations for drugmakers in India, accounting for roughly 33 per cent of the country's drug exports

Lincoln Pharma plans to foray into regulated markets, upgrades facility

The company has upgraded its manufacturing facility at Khatraj near Ahmedabad with Rs 30-crore investment

India scores better than US in regulatory action by USFDA in 2019

From FY15 to FY19, Indian manufacturers received fewer warning letters than Chinese counterparts

Prolonged coronavirus outbreak in China could hurt Indian pharma sector

China accounted for 67.56% of total imports of bulk drugs and drug intermediates in 2018-19 at $2,405.42 million.

Indian pharma cos with bigger US presence face more FDA scrutiny: Analysts

Big entities such as Aurobindo and Dr Reddy's have been currently filing for new product approvals from multiple sites

Indian pharma firms see fall in rate of final product approvals from USFDA

Analysts are optimistic that the sanction rate is likely to witness a pickup in the second half of the year.

Indian drug firms' growth slowed in 2017 on slow approvals, MNCs' caught up

GST rollout, more medicines being brought under price control, slow rate of drug approvals by NPPA hit Indian players, which control 80% of the domestic pharma market

Indian pharma should look beyond generics

Players need to step up investment in newer areas such as specialty drugs and biosimilars

Indian pharma lags on digital adoption: EY

Use of digital tools to gain customer insight, stakeholder engagement and disease management is limited

Indian pharma poised for US acquisitions

Mumbai, 7 AugustThe assets of Teva Pharmaceutical Industries have become acquisition targets following devastating results announced last week by the world's biggest maker of generic medicines.Teva's profits in the second quarter dropped to $1 billion from $1.23 billion a year earlier. Its stock slumped the most in almost two decades and the yield on its bonds jumped after the drugmaker warned that it might breach some debt covenants this year if sales did not rise.Soon, names of drug makers Fresenius, Mylan and Novartis started doing the rounds as buyers of some of Teva's assets, expected to be sold to repay debt.Teva's acquisition of Allergan's generic business last year for $40.5 billion has become troublesome as generic drugmakers' profit margins are being squeezed in the US, the world's biggest market. The Food and Drug Administration (FDA) is speeding up drug approvals, flooding the market with products from smaller companies that compete on price. It also came at a time when ...

Indian drug firms' R&D spending rises as growth slows in US, domestic mkts

Firms have spent around 9% of their operating income on research and development activities

Indian pharma's long road to redemption

IPA says its members need min 5 yrs to get manufacturing standards, data reliability up to scratch